IgG Functions - References

References

[1] . Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
[2] . Ortho multicentre transplant study group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New Engl J Med 1985; 313: 337-342.
[3] . Goldstein G. An overview of Orthoclone OKT3. Transplant Proc 1986; 18: 927-930.
[4] . Waldmann H. Manipulation of T-cell responses with monoclonal antibodies. Ann Rev Immunol 1989; 7: 407-444
[5] . Clark M, Cobbold S, Hale G, Waldmann H. Advantages of rat monoclonal antibodies. Immunol Today 1983; 4: 100-101.
[6] . Lachmann PJ. The control of homologous lysis. Immunol Today 1991; 12: 312-315.
[7] . Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement mediated lysis by monoclonal antibodies. Eur J Immunol 1988; 18: 1507-1514.
[8] . Hale G, Xia M, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118-127.
[9] . Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: Isotype specificity of antibody-dependant cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985; 134: 3056-3061.
[10] . Boulianne GL, Hozumi N, Schulman MJ. Production of functional chimaeric mouse/human antibody region domains. Nature 1984; 312: 643-646.
[11] . Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant Proc Natl Acad Sci USA 1984; 81:6851-6855.
[12] . Morrison SL, Oi VT. Transfer and expression of immunoglobulin genes. Ann Rev Immunol 1984; 2: 239-256.
[13] . Neuberger MS, Williams GT, Fox RO. Recombinant antibodies possessing novel effector functions. Nature 1984; 312: 604-608.
[14] . Neuberger MS, Williams GT, Mitchell EB, et al. A hapten-specific chimeric immunoglobulin E antibody which exhibits human physiological effector function. Nature 1985; 314: 268-271.
[15] . Bruggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166: 1351-136.
[16] . Shaw DR, Khazaeli MB, LoBuglio AF Mouse/human chimeric antibodies to a tumour-associated antigen: biological activity of the four human IgG subclasses. J Natl Cancer Inst 1988; 80: 1553-1559.
[17] . Steplewski Z, Sun LK, Shearman CW, et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 1988; 85: 4852-4856.
[18] . Riechmann L, Clark MR, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
[19] . Shin S, Wright A, Bonagura V, et al. Genetically-engineered antibodies: tools for the study of diverse properties of the antibody molecule. Immunol Rev 1992; 130: 87-107.
[20] . Xia M, Tone M, Packman L, et al. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991; 21: 1677-1684.
[21] . Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873-882.
[22] . Hale G, Dyer MJS, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-1399.
[23] . Hale G, Waldmann H, for CAMPATH users. CAMPATH-1 for prevention of graft-versus-host disease and graft rejection. Summary of results from a multi-centre study. Bone Marrow Transplantation 1988; 3 (suppl 1): 11-14.
[24] . Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. Effects of CAMPATH-1 antibodies in-vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431-1439.
[25] . Dyer MJS, Hale G, Marcus R, et al. Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies. Leukaemia and Lymphoma 1990; 2: 179-193
[26] . Mathieson PW, Cobbold SP, Hale G, et al. Monoclonal antibody therapy in systemic vasculitis. New Engl J Med 1990; 323: 250-254.
[27] . Isaacs JD, Watts RA, Hazleman BL, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. The Lancet 1992; 340: 748-752.
[28] . Bindon CI, Hale G, Bruggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168: 127-42.
[29] . Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991; 21: 11-16.
[30] . Valim YML, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol 1991; 84: 1-8.
[31] . Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions Eur J Immunol 1993; 5: 1098-1104.
[32] . Hale G, Cobbold SP, Waldmann H, et al. Isolation of low-frequency class-switch variants from rat hybrid myelomas. J Immunol Meth 1987; 103: 59-67.
[33] . Adair JR. Engineering antibodies for therapy. Immunol rev 1992; 130: 5-40.
[34] . Burton DR, Gregory L, Jefferis R. Aspects of the molecular Structure of IgG Subclasses. Monogr Allergy 1986; 19: 7-35
[35] . Jefferis R. Molecular structure of human IgG subclasses. In: Shakib F, ed. The Human IgG subclasses, Pergamon press. 1990: 15-30.
[36] . Tan LK, Shopes RJ, Oi VT, et al. Influence of the hinge region on complement activation , C1q binding, and segmental flexibility in human immunoglobulins. Proc Natl Acad Sci USA 1990; 87: 162-166.
[37] . Michaelsen TE, Aase A, Westby C, Sandlie I. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scand J Immunol 1990; 32: 517-528.
[38] . Duncan AR, Woof JM, Partridge LJ, et al. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988; 332: 563-564.
[39] . Jefferis R, Lund J, Pound J. Molecular definition of interaction sites on human IgG for Fc receptors (huFc gamma R). Molec Immunol 1990; 27: 1237-1240
[40] . Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991; 173: 1483-1491.
[41] . Chappel MS, Isenman DE, Everett M, et al. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point mutated antibodies. Proc Natl Acad USA 1991; 88: 9036-9040.
[42] . Sarmay G, Lund J, Rozsnyay Z, et al. Mapping and comparison of the interaction sites on the Fc region of IgG responsible for the triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcg receptor Molec Immunol. 1992; 29: 633-639.
[43] . Duncan AR, Winter G. The binding site for C1q on antibodies. Nature 1988; 332: 738-740.
[44] . Tao M, Canfield SM, Morrison SL.The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the the CH2 domain J Exp Med 1991;173: 1025-1028.
[45] . Diesenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from staphylococcus aureas at 2.9 and 2.8 angstroms resolution. Biochem 1981; 20 : 2361-2370.
[46] . WHO Review of the notation for the allotypic and related markers of human immunoglobulins. J Immunogen 1976; 3: 357-362.
[47] . Loghem E van. Allotypic markers. Monogr Allergy 1986; 19: 40-51.
[48] . Gorman SD, Clark MR. Humanisation of monoclonal antibodies for therapy. Sem Immunol 1990; 2: 457-466.
[49] . Tao M, Morrison SL. Studies of aglycoyslated chimeric mouse human IgG: Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region J Immunol 1989; 143: 2595-2601.
[50] . Lund J, Tanaka T, Takahashi N, et al. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma RI and huFc gamma RIII and/or activation. Mol Immunol 1990; 27: 1145-1153.
[51] . Bolt S, Routledge E, Lloyd I, et al. The generation of a humanised, non-mitogenic CD3 monoclonal antibody which retains in-vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403-411.
[52] . Whittingham S, Propert DN. Gm and Km Allotypes, Immune response and disease susceptibility. Monogr Allergy 1986; 19: 52-70.
[53] . Ravetch JV, Anderson CL. Fc gamma R Family: Proteins, Transcripts, and Genes. In: Metzler H, ed. Fc Receptors and the action of antibodies, American Society for Microbiology, Washington, USA 1991: 211-235.
[54] . Campbell RD, Law SKA, Reid KBM, et al. Structure, organization, and regulation of the complement genes. Ann Rev Immunol 1988; 6: 161-195.
[55] . Isaacs JD, Clark MR, Greenwood J Waldmann, H. Therapy with monoclonal antibodies - an in-vivo model for the assessment of therapeutic potential. J Immunol 1992; 148: 3062-3071.

Go to Contents